Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels

Schizophrenia Research

Volumn 98, Issue 1-3, 2008, Pages 40-46

  de Leon, Jose ^a,b   Correa, Juan Carlos ^c   Ruaño, Gualberto ^d   Windemuth, Andreas ^d   Arranz, Maria J ^e   Diaz, Francisco J ^c  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^d Genomas Inc   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acetyl coenzyme A carboxylase; Antipsychotics; Chlorpromazine; Cholesterol; Hypercholesterolemia; Hypertriglyceridemia; Lipids; Metabolic syndrome; Neuropeptide Y; Olanzapine; Quetiapine; Triglycerides

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ARIPIPRAZOLE; CHLORPROMAZINE; LIPID; NEUROLEPTIC AGENT; NEUROPEPTIDE Y; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; DNA MICROARRAY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHLORPROMAZINE; CROSS-SECTIONAL STUDIES; DIBENZOTHIAZEPINES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; LIPIDS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VARIATION (GENETICS);

EID: 36849095003     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.10.003     Document Type: Article

References (19)

1. Agresti A. Categorical Data Analysis (1990), John Wiley & Sons, New York
2. de Leon J., and Diaz F.J. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr. Res. 96 (2007) 185-197
3. de Leon J., Susce M.T., Johnson M., Hardin M., Pointer L., Ruaño G., Windemuth A., and Diaz F.J. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr. Res. 92 (2007) 95-102
4. Ellingrod V.L., Bishop J.R., Moline J., Lin Y.C., and Miller D.D. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol. Bull. 40 (2007) 57-62
5. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults. JAMA 287 (2002) 356-359
6. Harwood J.H. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Exp. Opin. Ther. Targets 9 (2005) 267-281
7. Koch W., Hoppman P., Mueller J.C., Schomig A., and Kastrini A. Association of transforming growth factor-Beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1114-1119
8. Kolsch H., Lutjohann D., Jessen F., Urbach H., von Bergmann K., Maier W., and Heun R. Polymorphism in neuropeptide Y influences CSF cholesterol levels but is not a major risk factor for Alzheimer's disease. J. Neural Transm. 113 (2006) 231-238
9. Kusunoki J., Kanatani A., and Moller D.E. Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndome. Endocrine 29 (2006) 91-100
10. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsaio J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
11. Markham-Abedi C., and de Leon J. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report (letter). J. Clin. Psychiatry 67 (2006) 1473-1474
12. Meyer J.M., and Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 70 (2004) 1-17
13. Pearson T.A. The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. Am. J. Cardiol. 94 (2004) 4F-8F
14. R Development Core Team, 2005. R. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org.
15. Ruaño G., Goethe J.W., Caley C., Woolley S., Holford T.R., Kocherla M., Windemuth A., and de Leon J. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol. Psychiatry 12 (2007) 474-482
16. Sasaki J., Funakoshi M., and Arakawa K. Lipids and apolipoproteins in patients treated with major tranquilizers. Clin. Pharmacol. Ther. 137 (1985) 684-687
17. SPSS, Inc. SPSS Advanced Statistics 7.5 (1997), SPSS, Inc., Chicago, IL
18. Turtzo L.C., and Lane M.D. NPY and neuron-adipocyte interactions in the regulation of metabolism. EXS 95 (2006) 133-141
19. Woodward M. Epidemiology: Study Design and Data Analysis (1999), Chapman & Hall/CRC, Boca Raton, FL